Author

P. Morlacchi

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:metabolism & bioenergetics· 1 Organism:mouse· 1

Frequent Co-Authors

C. A. Lyssiotis· 2 shared N. J. Rossiter· 2 shared Y. M. Shah· 2 shared A. D. Patterson· 1 shared A. M. Chinnaiyan· 1 shared A. Parolia· 1 shared B. Chen· 1 shared B. Magnuson· 1 shared

Activity by Year

2024-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

C. A. Lyssiotis

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Targeting PIKfyve-driven lipid homeostasis as a metabolic vulnerability in pancreatic cancer

C. Cheng, J. Hu, R. Mannan, R. Bhattacharyya, N. J. Rossiter, B. Magnuson, J. P. Wisniewski, Y. Zheng, L. Xiao, C. Li, D. Awad, T. He, Y. Bao, Y. Zhang, X. Cao, , A. M. Chinnaiyan

This study identifies PIKfyve as a targetable vulnerability in pancreatic cancer by showing its role in lipid metabolism and synthetic lethality with KRAS-MAPK inhibitors.

bioRxiv · Mar 18, 2024Cancer Biology

BRD4-mediated epigenetic regulation of endoplasmic reticulum-mitochondria contact sites is governed by the mitochondrial complex III

B. Chen, D. C. Stark, P. V. Jadhav, T. M. Lynn-Nguyen, B. S. Halligan, N. J. Rossiter, N. Sindoni, M. Shin, J. A. Paulo, M. Chang, I. Koo, S. Koshkin, S. Eyunni, P. Ronchi, M. T. Paulsen, , Y. M. Shah

The paper identifies fedratinib as a drug that increases endoplasmic reticulum-mitochondria contact sites by inhibiting BRD4, revealing a novel epigenetic pathway linking ERMCS to cellular metabolism.

bioRxiv · Feb 2, 2024 · PreprintCell Biology